Response from CGB, page-191

Morning eirexpat,

I really do understand that this has been a protracted affair & the Biohealth deal has certainly moved the goal posts again.

I hope I have not come across as in-sensitive to genuine shareholders like yourself who have lost patience, I struggle equally however at the same time I'm also aware to the challanges that CGB currently face & if not correctly managed we all stand to lose out greatly. On the other hand if managed correctly we stand to prosper.

Yes his wage is more than reasonable by anyones standards, many would be happy to trade incomes.

Sholom really needs the BioHealth & Vitahemp ventures to be profitable for CGB over the medium term. I feel it will be hard to raise further capital without reasonable revenue growth. When you also take shares on issue into consideration it also becomes another stress point for an under performing company to raise further capital, the elastic band will only bend so far before it breaks.

So with the current expenditures which includes a $1,000,000 annual investment in research & developement over in Isreal for our mm arm how many years can CGB last without producing revenue? Sure the current cash balance is healthy & all indications are that the cr will be fully subscribed to $6,000,000 from memory but these are not a means to the end.

Bottom line is Sholom will need to start kicking goals or I don't see the company moving past the next 4-5 years, which in turn means no healthy pay check each year.

These are high stake times eirexpat..I'm just hoping that for all the patience & risk taken by shareholders CGB get this right.

On paper the BioHealth deal sounds like a great opportunity, a succesful harvest would also have me breathing a sigh of relief.

Regards, Dan